产品
编 号：F229145
分子式：C37H65N9O13
分子量：843.96
分子式：C37H65N9O13
分子量：843.96
产品类型
规格
价格
是否有货
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
结构图
CAS No: 182683-50-7
产品详情
生物活性：
Epsilon-V1-2 (ε-V1-2), a PKCε-derived peptide, is a selective PKCε inhibitor. Epsilon-V1-2 inhibits the translocationof PKCε, but not α-, β-, and δPKC.
体内研究：
Epsilon-V1-2 (20 mg/kg/day; osmotic pumps; daily; for 4 weeks) treatment significantly improves the beating score in a murine heterotopic transplantation model. Epsilon-V1-2 reduces infiltration of macrophages and T cells into the cardiac grafts, and decreases parenchymal fibrosis. Epsilon-V1-2 treatment almost abolishes the rise in pro-fibrotic cytokine, TGF-β and monocyte recruiting chemokine MCP-1 levels.Animal Model:C57BL/6J mice transplanted the hearts of FVB mice
Dosage:20 mg/kg/day
Administration:0.1 mL osmotic pumps implanted subcutaneously; daily; for 4 weeks
Result:Significantly improved the beating score throughout the treatment.
体外研究：
Epsilon-V1-2 (ε-V1-2), a PKCε-derived peptide containing the site for its specific receptor for activated C kinase (RACK), inhibits translocation of PKCε and reduces insulin response to glucose.Epsilon-V1-2 (ε-V1-2; 1 μM, 24 hours) treatment significantly inhibits Oleic acid (OA)-induced connexin 43 (Cx43) Ser368 phosphorylation and prevents OA-induced gap junction disassembly in cardiomyocytes.
Epsilon-V1-2 (ε-V1-2), a PKCε-derived peptide, is a selective PKCε inhibitor. Epsilon-V1-2 inhibits the translocationof PKCε, but not α-, β-, and δPKC.
体内研究：
Epsilon-V1-2 (20 mg/kg/day; osmotic pumps; daily; for 4 weeks) treatment significantly improves the beating score in a murine heterotopic transplantation model. Epsilon-V1-2 reduces infiltration of macrophages and T cells into the cardiac grafts, and decreases parenchymal fibrosis. Epsilon-V1-2 treatment almost abolishes the rise in pro-fibrotic cytokine, TGF-β and monocyte recruiting chemokine MCP-1 levels.Animal Model:C57BL/6J mice transplanted the hearts of FVB mice
Dosage:20 mg/kg/day
Administration:0.1 mL osmotic pumps implanted subcutaneously; daily; for 4 weeks
Result:Significantly improved the beating score throughout the treatment.
体外研究：
Epsilon-V1-2 (ε-V1-2), a PKCε-derived peptide containing the site for its specific receptor for activated C kinase (RACK), inhibits translocation of PKCε and reduces insulin response to glucose.Epsilon-V1-2 (ε-V1-2; 1 μM, 24 hours) treatment significantly inhibits Oleic acid (OA)-induced connexin 43 (Cx43) Ser368 phosphorylation and prevents OA-induced gap junction disassembly in cardiomyocytes.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备